[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Nutrabuilding Bio-tech Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100617750","dihydroberberine-effects-on-body-composition-and-metabolic-health-in-healthy-adults-100617750",false,"NCT07322679","Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults","Effects of Dihydroberberine Supplementation on Body Composition, Glycemic Control, Energy Levels, Appetite, and Mood in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial","DHB","Inclusion Criteria:\n\n* 35 - 55 years of age (inclusive) at visit 1.\n* BMI ≥ 27.0 - ≤ 33.0 kg\u002Fm2.\n* Participant has a score of 7 - 10 on the Vein Access Scale Assessment at visit 1.\n* Non-user or former user (daily use; cessation ≥12 months) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, and has no plans to begin use during the study period.\n* Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including CBD\u002FTHC products, and willing to abstain from use throughout the study period (topical creams\u002Flotions are allowed).\n* Willing to use personal smart phone with operating system capable of downloading and operating study applications (e.g., FitBit, smart scale, activity watch, etc).\n* Willing to adhere to all study procedures, including lifestyle considerations (see section 6.3), and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n* Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan\u002Fvegetarian) at the discretion of the Clinical Investigator.\n* Individuals undergoing moderate-to-intense activity (e.g., sports\u002Fexercise ≥ 5h\u002Fwk).\n* Recent weight changes (\\>4.5 kg ≤ 90 d of visit 1), or current\u002Fplanned engagement in a weight change program (e.g., weight loss or muscle gain) outside of the researcher-instructed, self-directed Lifestyle Intervention throughout the study period.\n* Abnormal laboratory test results of clinical significance at visit 1, at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to visit 2, for subjects with abnormal laboratory test results.\n* Uncontrolled and\u002For clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and\u002For anxiety disorders) or biliary disorders. Conditions that are well-controlled or resolved will be assessed by the Clinical Investigator on a case-by-case basis.\n* Clinically important GI condition that would potentially interfere with the evaluation of the study product (e.g., inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, celiac disease, history of surgery for weight loss, gastroparesis, and clinically significant lactose or gluten intolerance or other food or ingredient allergies).\n* Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg. Stable use (no initiation or change in dose ≤ 90 d of visit 1) of FDA-approved medications for hypertension is allowed.\n* History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.\n* Signs or symptoms of an active infection of clinical relevance ≤ 5 d of visit 1. The visit may be rescheduled once all signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 d prior to visit 1.\n* Recent use (≤ 6 mo of visit 1) of any prescription anti-hyperglycemic\u002Fweight loss medication. This includes, but is not limited to: metformin, insulin, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonist, GIP agonists, Pioglitazone and Sulfonylureas.\n* Use of any dietary supplement, other than conventional once-daily multivitamin\u002Fmineral supplements (within limits of the DRI) ≤ 14 d of visit 1 and throughout the study.\n* Recent history (≤ 12 months visit 1) of alcohol or substance abuse. Alcohol abuse is defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).\n* Unstable use (change in dose) of any other prescription medications ≤ 90 d of visit 1, except for medications used PRN (e.g., asthma inhalers, non-drowsy seasonal allergy medications, etc.)\n* Antibiotic use ≤ 90 d of visit 1 and throughout the study period.\n* Regular use (≥ 3 days\u002Fweek ≤ 30 d of visit 1) of anti-inflammatory medications (e.g., NSAIDs) and throughout the study period.\n* Recent use of oral or injectable steroids, or topical or inhaled steroids (≥ 1500 µg\u002Fd) within 30 d of visit 1 and throughout the study period.\n* Exposure to any non-registered drug product ≤ 30 d prior to visit 1.\n* Diagnosed with major affective disorder, or other psychiatric disorder, that required hospitalization ≤ 12 months prior to visit 1.\n* Recent (≤ 90 d of visit 1) endoscopy and\u002For colonoscopy procedure.\n* Major trauma or any other surgical event ≤ 30 d of visit 1.\n* Currently scheduled, or planning to schedule, an elective surgical procedure during the study.\n* Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. Women who become pregnant during the study will be discontinued.\n\nGeneral safety related criteria\n\n* Known sensitivity, intolerability, or allergy to any of the study products or study foods.\n* Has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, and comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.",true,"ALL","35 Years","55 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this clinical trial is to evaluate whether dihydroberberine (DHB) supplementation can improve body composition, blood sugar control, energy levels, appetite, and mood in healthy adults with overweight or mild obesity. The study focuses on men and women aged 35-55 years with a BMI between 27.0 and 33.0 kg\u002Fm².\n\nThe main questions it aims to answer are:\n\nDoes daily DHB supplementation lead to greater reductions in body weight over 12 weeks compared to placebo? Does DHB improve glycemic responses, appetite regulation, energy levels, and mood, both acutely (short-term) and chronically (over 12 weeks)?\n\nResearchers will compare two groups-one receiving DHB (400 mg\u002Fday) and the other receiving a placebo-administered as two capsules twice daily for 12 weeks. Participants will:\n\nAttend three in-clinic visits over approximately 14 weeks (including screening, baseline, and week 12 visits) Undergo mixed-meal tolerance tests (MTTs) to assess glucose metabolism, appetite, and energy levels Complete body composition assessments (including DXA scans), blood tests (e.g., glucose, insulin, HbA1c), and mood questionnaires (POMS-2) Be monitored for safety throughout the study",[29],"Health Adult Subjects",[31,15,32,33,34,35,36,37,38,39,40,41,42,43],"Glucovantage®","Dihydroberberine","Body Composition","Glycemic Control","Energy Levels","Appetite","Mood","metabolism","Blood glucose","Body weight management","Waist circumference","Hip circumference","Leptin","NOT_YET_RECRUITING","2025-12-29",{"date":47,"type":48},"2026-01-07","ACTUAL",{"date":50,"type":23},"2025-12-15",{"date":52,"type":23},"2026-09-25",{"name":54,"class":55},"Nanjing Nutrabuilding Bio-tech Co., Ltd.","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":17,"sex":18,"minAge":64,"maxAge":20,"enrollmentInfo":65,"targetDuration":4,"studyType":24,"phases":67,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":56},"100613534","the-effect-of--gpc-on-cognitive-function-and-sports-performance-100613534","NCT07267845","The Effect of α-GPC on Cognitive Function and Sports Performance","A Randomised, Double-Blind, Placebo-Controlled Study on the Effects of Alpha-Glycerophosphocholine (α-GPC) on Cognitive Function and Sports Performance in Adults","Inclusion Criteria:\n\n* Be able to give written informed consent.\n* Be in good health as determined by the investigator.\n* Age between 25 and 55 years (inclusive).\n* Body Mass Index of 18.5-32.0 kg\u002Fm2 (inclusive).\n* Body weight of at least 54 kilograms.\n* Muscle strengthening activities 2-3 time per week or participation in recreational or local level moderate intensity activity for at least 2 years.\n* Normotensive (resting systolic blood pressure \\\u003C140 mm Hg and diastolic blood pressure \\\u003C 90 mm Hg).\n* Willing to duplicate their previous 24-hr diet, refrain from alcohol and caffeine for 24-hr prior to each visit, refrain from exercise 48-hr prior to each visit.\n* Refrain from consuming beef liver, chicken liver, eggs, fish, wheat germ and soybeans, butter beans 24-hrs prior to Visit 2 and Visit 3.\n\nExclusion Criteria:\n\n* Highly trained or competitive athletes.\n* Participants who are pregnant or wish to become pregnant during the study or who are lactating and\u002For currently breastfeeding.\n* Female participants who are currently breastfeeding.\n* Female participants who are planning to become pregnant during the study period.\n* Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product.\n* Participants with history of drug and\u002For alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\\>11 units for women; \\>17 units for men); alcohol\u002Fsubstance abuse disorder).\n* Caffeine intake of three or more cups of coffee or equivalent (\\>400 mg) per day.\n* Current smokers or users of any nicotine products in the past 4-weeks.\n* Has food allergies or other issues with foods that would preclude intake of the Study Products.\n* Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.\n* History of malignancy in the previous 5 years except for non-melanoma skin cancer.\n* Diagnosed, uncontrolled psychiatric disorder.\n* Hepatorenal, musculoskeletal, autoimmune, or neurologic disease.\n* Prior gastrointestinal bypass surgery (excluding appendectomy).\n* Gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism.\n* Chronic inflammatory condition or disease.\n* History of severe or chronic musculoskeletal pain or injury.\n* History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS\u002FIBD.\n* Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.\n* Use CNS stimulants or anxiety or ADHD medication.\n* Use corticosteroids (oral, subcutaneous, intramuscular, or transdermal only).\n* Use testosterone replacement therapy (ingestion, injection, or transdermal).\n* Current or recent use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.\n* Use creatine, BCAA, HMB, betaine, beta-alanine, in the past 2 weeks.\n* Use choline supplements (e.g. choline bitartrate, phosphatidylcholine, citicholine) in the past 4 weeks.\n* Use omega-3, ginkgo biloba, ginseng, L-theanine, Lion's Mane, ashwagandha in the past 4 weeks.\n* Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.\n* Participants may be participating in other clinical studies.","25 Years",{"count":66,"type":23},80,[26],"The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period.\n\nThe main questions this study aims to answer are:\n\nDoes taking α-GPC every day improve cognitive performance on tests such as the Stroop Test, Go\u002FNo-go Test, Sustained Attention to Response Task (SART), and Digit-Symbol Substitution Test (DSST)? Does α-GPC enhance upper and lower body sports performance? Does α-GPC positively affect perceived mood, energy, and motivation? Is α-GPC safe and well tolerated compared to a placebo? Researchers will compare α-GPC (350 mg per day) to a placebo (an inactive substance that looks the same) in a randomized, double-blind study. Neither the participants nor the researchers will know who receives α-GPC or the placebo.\n\nParticipants will:\n\nBe randomly assigned to take either α-GPC or placebo capsules once daily for 6 weeks Attend 3 study visits over an 8-week period at Atlantia Clinical Trials in Cork, Ireland Complete cognitive and physical performance tests both acutely (shortly after a single dose) and after 6 weeks of daily use Have their vital signs, body weight, and any adverse events monitored throughout the study Record their diet and well-being during the study period This study will include 80 healthy adults aged 25-55 years who regularly engage in physical activity. The results will help determine whether α-GPC has benefits for brain function and physical performance, and whether it is safe for long-term use.",[70],"Healthy Participants",[72,73,74,75,76,77],"Alpha-Glycerophosphocholine","α-GPC","cognitive function","sports performance","Dietary Supplement","safety","RECRUITING","2025-12-07",{"date":81,"type":48},"2025-12-09",{"date":83,"type":48},"2025-10-21",{"date":85,"type":23},"2026-07-05",{"name":54,"class":55},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":15,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":24,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":56},"100609140","effects-of-dihydroberberine-dhb-on-glp-1-glycemic-control-appetite-and-mood-in-adults-with-pre-diabetes-100609140","NCT07210684","Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes","A Randomized, Double-Blind, Placebo-Controlled Trial on the Effects of Dihydroberberine (DHB) on Glucagon-Like Peptide-1 (GLP-1), Glycemic Control, and Subjective Rating of Appetite and Mood\u002FEnergy in Adults With Pre-Diabetes","Inclusion Criteria:\n\n1.35 - 65 years of age (inclusive). 2.BMI 25.0 - 35.0 kg\u002Fm2 (inclusive). 3.HbA1c 5.7% - 6.4% (39 - 47 mmol\u002Fmol, inclusive) measured at visit 1. 4.Participant has a score of 7 - 10 on the Vein Access Scale Assessment at visit 1.\n\n5.Non-user or former user (daily use; cessation ≥12 months) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, and has no plans to begin use during the study period.\n\n6.Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including CBD\u002FTHC products, and willing to abstain from use throughout the study period (topical creams\u002Flotions are allowed).\n\n7.Willing to wear a CGM sensor throughout study period and willing to adhere to instructions\u002F restrictions associated with the proper use and care of the CGM.\n\n8.Willing to use personal smart phone with operating system capable of downloading and operating the Cronometer and Dexcom CGM apps for diet records and blood glucose, respectively.\n\n9.Willing to adhere to all study procedures, including lifestyle considerations, and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n1. Extreme Diets: Extreme dietary habits (e.g., ketogenic, vegan\u002Fvegetarian) at investigator's discretion.\n2. Intense Exercise: Moderate-to-intense physical training (≥5 hours\u002Fweek).\n3. Weight Instability\u002FProgram: Recent weight changes (\\>4.5 kg≤90 d) or current\u002Fplanned weight change program.\n4. Abnormal Labs: Abnormal lab test results of clinical significance at Visit 1 (one re-test allowed).\n5. Uncontrolled Chronic Illness: Uncontrolled or clinically important pulmonary, cardiac, hepatic, renal, endocrine (T1D\u002FT2D excluded), hematologic, immunologic, neurologic, psychiatric, or biliary disorders.\n6. Clinically Important GI: Clinically important GI condition interfering with study product (e.g., IBD, celiac, weight loss surgery history).\n7. Uncontrolled HTN: Uncontrolled hypertension (SBP≥160 mmHg and\u002For DBP≥100 mmHg).\n8. Cancer History: History or presence of cancer in the prior 2 years (except non-melanoma skin cancer).\n9. Active Infection: Signs\u002Fsymptoms of active infection ≤5 d of Visit 1.\n10. Anti-Hyperglycemics: Recent use (≤6 mo) of any prescription anti-hyperglycemic medication.\n11. Other Supplements: Use of dietary supplements (other than approved multivitamin) ≤14 d of Visit 1.\n12. Alcohol\u002FSubstance Abuse: History (≤12 months) of alcohol (\\>14 drinks\u002Fweek) or substance abuse.\n13. Antibiotics: Antibiotic use ≤90 d of Visit 1.\n14. Regular NSAIDs: Regular use (≥3 days\u002Fweek≤30 d) of anti-inflammatory medications.\n15. Steroid Use: Recent use (≤30 d) of oral\u002Finjectable steroids, or high-dose topical\u002Finhaled steroids.\n16. Unregistered Drug: Exposure to any non-registered drug product ≤30 d prior to Visit 1\n17. Medication Instability: Unstable dose (≤90 d) of any other prescription medications (PRN excluded).\n18. Psychiatric Hospitalization: Major affective\u002Fpsychiatric disorder requiring hospitalization ≤12 months prior to Visit 1.\n19. Recent Trauma\u002FSurgery: Major trauma or any surgical event ≤30 d of Visit 1.\n20. Recent GI Prep: Endoscopy or colonoscopy preparation ≤90 d prior to Visit 1.\n21. Planned Surgery: Scheduled or planning elective surgical procedures during the study.\n22. Female Status: Pregnancy, lactation, planning pregnancy, or unwillingness to use approved contraception.\n23. Allergies: Known sensitivity or allergy to any study products or foods.\n24. Investigator Discretion: Any condition that interferes with compliance, confounds results, or presents undue risk.","65 Years",{"count":96,"type":23},54,[26],"The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes.\n\nThe main questions it aims to answer are:\n\nDoes DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy levels? Does DHB supplementation affect body weight, blood sugar control and insulin? Researchers will compare DHB supplementation to a placebo (a look-alike substance that contains no drug) to see if DHB has any effect.\n\nParticipants will:\n\nTake DHB or a placebo every day for 6 weeks. Participate in tests to measure GLP-1 levels, blood glucose, insulin and other markers.\n\nHave their continuous blood sugar profiles (with CGMs) monitored to see how much time their blood sugar spends in a healthy range.\n\nRate their appetite, mood, and energy levels using a visual analog scale.",[100],"Prediabetes",[102,15,32,103,104,39,105],"GlucoVantage®","GLP-1","Glucagon-Like Peptide-1","Appetite and Mood\u002FEnergy","2025-09-29",{"date":108,"type":48},"2025-10-07",{"date":110,"type":48},"2025-08-06",{"date":112,"type":23},"2026-03-15",{"name":54,"class":55},""]